O Babuŝíková

822 total citations
83 papers, 677 citations indexed

About

O Babuŝíková is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Hematology. According to data from OpenAlex, O Babuŝíková has authored 83 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Public Health, Environmental and Occupational Health, 23 papers in Molecular Biology and 22 papers in Hematology. Recurrent topics in O Babuŝíková's work include Acute Lymphoblastic Leukemia research (32 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Lymphocytic Leukemia Research (16 papers). O Babuŝíková is often cited by papers focused on Acute Lymphoblastic Leukemia research (32 papers), Acute Myeloid Leukemia Research (19 papers) and Chronic Lymphocytic Leukemia Research (16 papers). O Babuŝíková collaborates with scholars based in Slovakia, Czechia and Austria. O Babuŝíková's co-authors include Silvia Pastoreková, J Závada, Zuzana Závadová, Michael Košťál, Peter Ujházy, Esko Kankuri, Enrico Mihich, Paul H. Strausbauch, M. Jane Ehrke and Jana Stasakova and has published in prestigious journals such as International Journal of Cancer, Virology and Archives of Virology.

In The Last Decade

O Babuŝíková

79 papers receiving 659 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
O Babuŝíková Slovakia 11 339 184 132 117 117 83 677
D. M. Moccio United States 16 393 1.2× 133 0.7× 260 2.0× 289 2.5× 43 0.4× 21 920
R. Pelka‐Fleischer Germany 15 277 0.8× 206 1.1× 279 2.1× 62 0.5× 46 0.4× 27 653
Masanori Umeda Japan 15 275 0.8× 113 0.6× 145 1.1× 46 0.4× 30 0.3× 59 533
Linda Hogarth United Kingdom 14 387 1.1× 91 0.5× 152 1.2× 232 2.0× 82 0.7× 29 666
G R Westerhof Netherlands 17 442 1.3× 248 1.3× 238 1.8× 181 1.5× 37 0.3× 25 912
Ruud Oerlemans Netherlands 13 583 1.7× 305 1.7× 445 3.4× 75 0.6× 63 0.5× 23 1.2k
Timothy J. Hoy United Kingdom 19 504 1.5× 189 1.0× 240 1.8× 77 0.7× 54 0.5× 34 896
Anna Korycka Poland 17 304 0.9× 162 0.9× 114 0.9× 87 0.7× 20 0.2× 51 781
Kourosh Lotfi Sweden 18 400 1.2× 383 2.1× 264 2.0× 141 1.2× 71 0.6× 54 968
Ota Fuchs Czechia 18 569 1.7× 444 2.4× 164 1.2× 37 0.3× 101 0.9× 67 1.0k

Countries citing papers authored by O Babuŝíková

Since Specialization
Citations

This map shows the geographic impact of O Babuŝíková's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O Babuŝíková with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O Babuŝíková more than expected).

Fields of papers citing papers by O Babuŝíková

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by O Babuŝíková. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O Babuŝíková. The network helps show where O Babuŝíková may publish in the future.

Co-authorship network of co-authors of O Babuŝíková

This figure shows the co-authorship network connecting the top 25 collaborators of O Babuŝíková. A scholar is included among the top collaborators of O Babuŝíková based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with O Babuŝíková. O Babuŝíková is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Babuŝíková, O, et al.. (2008). Hematogones in acute leukemia during and after therapy. Leukemia & lymphoma. 49(10). 1935–1944. 27 indexed citations
3.
Kankuri, Esko, O Babuŝíková, K Hlubinová, et al.. (2007). Fibroblast nemosis arrests growth and induces differentiation of human leukemia cells. International Journal of Cancer. 122(6). 1243–1252. 26 indexed citations
4.
Babuŝíková, O, et al.. (2006). The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.. PubMed. 53(6). 500–6. 14 indexed citations
5.
Babuŝíková, O, et al.. (2005). The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.. PubMed. 52(6). 517–22. 6 indexed citations
6.
Babuŝíková, O, et al.. (2004). Analysis of surface and cytoplasmic immunoglobulin light/heavy chains by flow cytometry using a lysed-whole-blood technique: Implications for the differential diagnosis of B-cell malignancies.. PubMed. 51(6). 422–30. 4 indexed citations
7.
Babuŝíková, O, et al.. (1999). Flow cytometric analysis of some activation/proliferation markers on human thymocytes and their correlation with cell proliferation.. PubMed. 46(6). 349–55. 1 indexed citations
8.
Babuŝíková, O, et al.. (1998). Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPP IV enzyme expression.. PubMed. 45(4). 237–42. 4 indexed citations
9.
Babuŝíková, O, et al.. (1996). Flow cytometric detection of some activation and proliferation markers in human hematopoietic cell lines.. PubMed. 43(6). 381–8. 3 indexed citations
10.
Babuŝíková, O, et al.. (1996). The study of AgNOR proteins in leukemias: diagnostic value and correlation to S-phase cell fraction.. PubMed. 43(6). 397–401. 7 indexed citations
11.
Babuŝíková, O, et al.. (1996). Some early differentiation markers detected in cytoplasm of pre-B cells by flow cytometry.. PubMed. 43(6). 373–9. 1 indexed citations
12.
Ujházy, Peter, et al.. (1994). Ecto‐5'‐nucleotidase (CD73) in multidrug‐resistant cell lines generated by doxorubicin. International Journal of Cancer. 59(1). 83–93. 38 indexed citations
13.
Zajac, Vladimír, et al.. (1994). Expression of env gene of bovine leukemia virus in rodent cells. Archives of Virology. 135(1-2). 201–207. 1 indexed citations
14.
Pastoreková, Silvia, Zuzana Závadová, Michael Košťál, O Babuŝíková, & J Závada. (1992). A novel quasi-viral agent, MaTu, is a two-component system. Virology. 187(2). 620–626. 237 indexed citations
15.
Babuŝíková, O, et al.. (1991). Purine metabolism enzyme pattern, cytochemical characteristics and clinicopathologic features of CD10-positive childhood T-cell leukemia.. PubMed. 38(6). 595–602. 1 indexed citations
16.
Nn, Tupitsyn, et al.. (1990). Clinical significance of standard CD assessment in acute leukemia.. PubMed. 37(4). 431–8. 2 indexed citations
17.
Rychly, Joachim, et al.. (1984). Cell electrophoretic characterization of peripheral blood lymphocyte subpopulations enriched by rosette formation, from normal individuals and CLL patients.. PubMed. 31(1). 57–64. 1 indexed citations
18.
Babuŝíková, O, et al.. (1978). Mutual relationship between total and active T lymphocytes in patients with malignant tumors.. PubMed. 25(1). 67–74. 1 indexed citations
19.
Babuŝíková, O, et al.. (1975). Change in the proportion of T and B lymphocytes in human malignant neoplasia in relation to the clinical stage.. PubMed. 22(4). 413–21. 4 indexed citations
20.
Babuŝíková, O, et al.. (1965). Experiences with malignant brain tumours in clinic and in tissue culture. Acta Neurochirurgica. 13(3-4). 393–406. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026